Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30666
Title: | Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study | Authors: | Chichareon, Ply Modolo, Rodrigo Kogame, Norihiro Takahashi, Kuniaki Chang, Chun-Chin Tomaniak, Mariusz Botelho, Roberto Eeckhout, Eric Hofma, Sjoerd Trendafilova-Lazarova, Diana Koszegi, Zsolt Iniguez, Andres Wykrzykowska, Joanna J. Piek, Jan J. Garg, Scot Hamm, Christian Steg, Philippe Gabriel Juni, Peter VRANCKX, Pascal Valgimigli, Marco Windecker, Stephan Onuma, Yoshinobu Serruys, Patrick W. |
Issue Date: | 2020 | Publisher: | ELSEVIER IRELAND LTD | Source: | ATHEROSCLEROSIS, 295 , p. 45 -53 | Abstract: | Background and aims: Diabetes has been well recognized as a strong predictor for adverse outcomes after percutaneous coronary intervention (PCI), however, studies in the era of drug-eluting stent and potent P2Y12 inhibitors have shown conflicting results. We aimed to assess ischemic and bleeding outcomes after contemporary PCI according to diabetic status. Methods: We studied 15,957 patients undergoing PCI for stable or acute coronary syndrome in the GLOBAL LEADERS study with known baseline diabetic status. The primary endpoint was all-cause death or new Q-wave myocardial infarction at 2 years. The secondary safety endpoint was major bleeding defined as bleeding academic research consortium (BARC) type 3 or 5. Results: A quarter of the study cohort were diabetic (4038/15,957), and these patients had a significantly higher risk of primary endpoint at 2 years compared to non-diabetics (adjusted hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.17-1.63). The difference was driven by a significantly higher risk of all-cause mortality at 2 years in diabetics (adjusted HR 1.47, 95% CI 1.22-1.78). The risk of BARC 3 or 5 bleeding was comparable between the two groups (adjusted HR 1.09, 95% CI 0.86-1.39). The antiplatelet strategy (experimental versus reference strategy) had no significant effect on the rates of primary endpoint and secondary safety endpoint at 2 years in patients with and without diabetes. Conclusions: Diabetic patients had higher risk of ischemic events after PCI than non-diabetic patients, whilst bleeding risk was comparable. The outcomes of diabetic patients following PCI were not affected by the two different antiplatelet strategies. | Notes: | Serruys, PW (reprint author), POB 2125, NL-3000 CC Rotterdam, Netherlands. patrick.w.j.c.serruys@gmail.com |
Other: | Serruys, PW (reprint author), POB 2125, NL-3000 CC Rotterdam, Netherlands. patrick.w.j.c.serruys@gmail.com | Keywords: | Coronary artery disease;Diabetes;Percutaneous coronary intervention;Ticagrelor;Drug-eluting stents | Document URI: | http://hdl.handle.net/1942/30666 | ISSN: | 0021-9150 | e-ISSN: | 1879-1484 | DOI: | 10.1016/j.atherosclerosis.2020.01.002 | ISI #: | WOS:000512990500007 | Rights: | 2020 Elsevier B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ply.pdf Restricted Access | Published version | 1.42 MB | Adobe PDF | View/Open Request a copy |
Impact_of_diabetes_GL _coauthors (1).pdf | Peer-reviewed author version | 1.01 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
37
checked on Sep 28, 2024
Page view(s)
36
checked on Jul 20, 2022
Download(s)
44
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.